Commissioning Agents, Inc | CAI Consulting
Company Employees
Rich Stanfield
Vice President, North America @Commissioning Agents, Inc | CAI Consulting
Verified
NA
Nick Armstrong
Sr Director, Digital Enablement @Commissioning Agents, Inc | CAI Consulting
Verified
Nick Armstrong is a seasoned technology and business leader with over 20 years of experience at the intersection of life sciences, digital transformation, and AI innovation. He has led large-scale digital twin programs, architected AI-driven operational strategies, and built scalable knowledge management frameworks in regulated, GxP-compliant environments. Nick currently serves as Senior Director of Digital Enablement at CAI, where he founded and leads a digital transformation division responsible for embedding AI, knowledge graphs, and semantic data models into core consulting and operational services. His work has enabled enterprise-wide efficiency gains, including a 50% reduction in labor for commissioning and qualification services through AI-powered automation. Previously, Nick served as Practice Lead for Asset Management & Reliability, where he quadrupled practice revenue by implementing predictive analytics, harmonized maintenance strategies, and structured delivery systems across multiple client sites. Prior to CAI, he held engineering and leadership roles at Genentech, where he developed patented drug delivery technologies, deployed robotics in high-throughput manufacturing, and led global reliability programs resulting in multimillion-dollar cost savings. He is also a recognized industry thought leader, serving as Co-Chair of ISPE’s AI Community of Practice. He has contributed to FDA- and ISPE-endorsed AI validation frameworks and regularly advises regulators and global pharma on digital maturity, AI adoption, and deterministic compliance strategies. Nick’s cross-functional fluency, from platform architecture and AI product strategy to commercial engagement and regulatory compliance, positions him uniquely to lead digital initiatives across biotech, pharma, and AI.More...